ATE465149T1 - Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen - Google Patents
Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänenInfo
- Publication number
- ATE465149T1 ATE465149T1 AT97907937T AT97907937T ATE465149T1 AT E465149 T1 ATE465149 T1 AT E465149T1 AT 97907937 T AT97907937 T AT 97907937T AT 97907937 T AT97907937 T AT 97907937T AT E465149 T1 ATE465149 T1 AT E465149T1
- Authority
- AT
- Austria
- Prior art keywords
- immunophilin
- chimeric proteins
- rapamycin derivatives
- derived domain
- multimerizing agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1243296P | 1996-02-28 | 1996-02-28 | |
| US2486196P | 1996-08-28 | 1996-08-28 | |
| US3303596P | 1996-12-10 | 1996-12-10 | |
| PCT/US1997/003137 WO1997031898A1 (en) | 1996-02-28 | 1997-02-28 | Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE465149T1 true ATE465149T1 (de) | 2010-05-15 |
Family
ID=27359637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97907937T ATE465149T1 (de) | 1996-02-28 | 1997-02-28 | Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0888303B1 (de) |
| JP (2) | JP4936345B2 (de) |
| AT (1) | ATE465149T1 (de) |
| AU (2) | AU731826B2 (de) |
| CA (1) | CA2244363C (de) |
| DE (1) | DE69739853D1 (de) |
| WO (2) | WO1997031898A1 (de) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4936345B2 (ja) * | 1996-02-28 | 2012-05-23 | アリアド・ファーマシューティカルズ・インコーポレイテッド | イムノフィリン由来ドメインとのキメラタンパク質用の多量体化剤としてのラパマイシンの合成誘導体 |
| US5945441A (en) * | 1997-06-04 | 1999-08-31 | Gpi Nil Holdings, Inc. | Pyrrolidine carboxylate hair revitalizing agents |
| WO1999041258A1 (en) * | 1998-02-13 | 1999-08-19 | President And Fellows Of Harvard College | Novel dimerizing agents, their production and use |
| US6984635B1 (en) | 1998-02-13 | 2006-01-10 | Board Of Trustees Of The Leland Stanford Jr. University | Dimerizing agents, their production and use |
| WO1999050425A2 (en) * | 1998-03-30 | 1999-10-07 | Baylor College Of Medicine | Regulated apoptosis using chemically induced dimerization of apoptosis factors |
| CN101245043B (zh) * | 1998-06-03 | 2013-02-13 | Gpinil控股公司 | N-杂环化合物的羧酸和羧酸电子等排物 |
| US6331537B1 (en) * | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
| JP4722288B2 (ja) * | 1998-06-03 | 2011-07-13 | ジーピーアイ ニル ホールディングス インコーポレイテッド | 神経学上の傷害および毛髪損失を治療するために使用されるａｚａ−複素環式化合物 |
| US6300341B1 (en) | 1998-09-30 | 2001-10-09 | The Procter & Gamble Co. | 2-substituted heterocyclic sulfonamides |
| US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
| US6566073B1 (en) | 1998-10-19 | 2003-05-20 | Ariad Gene Therapeutics, Inc. | Materials and methods involving conditional retention domains |
| AU3770800A (en) | 1999-03-26 | 2000-10-16 | Amgen, Inc. | Beta secretase genes and polypeptides |
| BR0012327A (pt) | 1999-07-09 | 2002-07-02 | Ortho Mcneil Pharm Inc | Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados |
| WO2001010837A1 (en) * | 1999-08-05 | 2001-02-15 | The Procter & Gamble Company | Multivalent sulfonamides |
| WO2001010836A1 (en) * | 1999-08-05 | 2001-02-15 | The Procter & Gamble Company | Method of treating hair loss using multivalent ketoamides and amides |
| WO2001010838A1 (en) * | 1999-08-05 | 2001-02-15 | The Procter & Gamble Company | Multivalent compounds |
| US7408047B1 (en) | 1999-09-07 | 2008-08-05 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US6900043B1 (en) | 1999-09-21 | 2005-05-31 | Amgen Inc. | Phosphatases which activate map kinase pathways |
| EP1125925A1 (de) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amin-Derivate zur Behandlung von Apoptosis |
| AR030554A1 (es) | 2000-03-16 | 2003-08-27 | Amgen Inc | Moleculas similares a receptores il-17 y usos de las mismas |
| US7514239B2 (en) | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
| JP2004519205A (ja) | 2000-06-28 | 2004-07-02 | アムジェン インコーポレイテッド | 胸腺間質リンホポイエチンレセプター分子およびその使用 |
| US7662924B2 (en) | 2002-02-22 | 2010-02-16 | The Board Of Trustees Of The University Of Illinois | Beta chain-associated regulator of apoptosis |
| ES2249986B1 (es) * | 2004-07-02 | 2007-02-01 | Universidad Complutense De Madrid | Sintesis de derivados fluorescentes de tacrolimus (fk506) y su uso en la caracterizacion de la interaccion de fk506 con proteinas de union a fk506. |
| US7629315B2 (en) | 2005-03-09 | 2009-12-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions for blocking the inhibitory effect of human CRP on human leptin |
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| NZ592009A (en) | 2008-10-10 | 2012-11-30 | Amgen Inc | Fgf21 mutants and uses thereof |
| AU2010246038A1 (en) | 2009-05-05 | 2011-12-01 | Amgen Inc. | FGF21 mutants and uses thereof |
| SI3248610T1 (sl) | 2009-05-05 | 2024-03-29 | Amgen Inc., | Mutanti fgf21 in njihove uporabe |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| AU2011238708B2 (en) | 2010-03-29 | 2016-02-11 | The Trustees Of The University Of Pennsylvania | Pharmacologically Induced Transgene Ablation system |
| US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| EP3670534A3 (de) | 2010-04-15 | 2020-09-09 | Amgen Inc. | Humaner fgf-rezeptor und beta-klotho-bindeproteine |
| EP3699286A1 (de) | 2011-04-20 | 2020-08-26 | The Trustees of the University of Pennsylvania | Dosierpläne und zusammensetzungen zur aav-vermittelten passiven immunisierung von luftbürtigen krankheitserregern |
| WO2013186264A1 (en) | 2012-06-12 | 2013-12-19 | Universitätsspital Basel | Immortalized mesenchymal stem cells that can be killed through an inducible apoptosis system |
| US9719106B2 (en) | 2013-04-29 | 2017-08-01 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof |
| CN103242218B (zh) * | 2013-05-24 | 2015-04-15 | 深圳市天和医药科技开发有限公司 | N-取代哌可酸衍生物及其制备方法与应用 |
| EP3129470B1 (de) | 2014-04-07 | 2021-04-07 | Novartis Ag | Behandlung von krebs mittels chimärem anti-cd19-antigenrezeptor |
| KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
| EP3240803B1 (de) | 2014-12-29 | 2021-11-24 | Novartis AG | Verfahren zur herstellung von chimären antigenrezeptor-exprimierenden zellen |
| PL3280729T3 (pl) | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| CN108473957A (zh) | 2015-04-17 | 2018-08-31 | 诺华股份有限公司 | 改善嵌合抗原受体表达细胞的功效和扩增的方法 |
| AU2016275909A1 (en) | 2015-05-13 | 2017-11-09 | The Trustees Of The University Of Pennsylvania | AAV-mediated expression of anti-influenza antibodies and methods of use thereof |
| US10829735B2 (en) | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
| US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
| US20180230489A1 (en) | 2015-10-28 | 2018-08-16 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
| US20210177896A1 (en) | 2016-06-02 | 2021-06-17 | Novartis Ag | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
| SG10201913823VA (en) | 2016-10-07 | 2020-03-30 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
| WO2018094195A1 (en) | 2016-11-21 | 2018-05-24 | Tribiotica Llc | Methods for directed folding assembly or dimerization of proteins by templated assembly reactions |
| WO2018094070A1 (en) | 2016-11-21 | 2018-05-24 | Tribiotica Llc | Methods for preventing titration of bimolecular templated assembly reactions by structurally-determined differential hybridizations |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| CA3052487A1 (en) | 2017-02-28 | 2018-09-07 | The Trustees Of The University Of Pennsylvania | Influenza vaccines based on aav vectors |
| US11827906B2 (en) | 2017-02-28 | 2023-11-28 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) clade f vector and uses therefor |
| AU2018270515A1 (en) | 2017-05-19 | 2019-12-05 | The Regents Of The University Of California | Antibody chemically induced dimerizer (abCID) as molecular switches for regulating cellular therapies |
| EP3700926A1 (de) | 2017-10-25 | 2020-09-02 | Novartis AG | Verfahren zur herstellung von chimären antigenrezeptor-exprimierenden zellen |
| US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| EP3802825A1 (de) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Zusammensetzungen und verfahren zur immunonkologie |
| US20210171909A1 (en) | 2018-08-31 | 2021-06-10 | Novartis Ag | Methods of making chimeric antigen receptor?expressing cells |
| MX2021002393A (es) | 2018-08-31 | 2021-07-15 | Novartis Ag | Metodos de preparacion de celulas que expresan receptores de antigenos quimericos. |
| US20220047633A1 (en) | 2018-09-28 | 2022-02-17 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
| US20210347851A1 (en) | 2018-09-28 | 2021-11-11 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
| CN109734655B (zh) * | 2019-03-11 | 2020-06-02 | 都创(上海)医药科技有限公司 | 一种fkbp配体的同型二聚体合成工艺 |
| EP3953455A1 (de) | 2019-04-12 | 2022-02-16 | Novartis AG | Verfahren zur herstellung von zellen zur expression des chimären antigenrezeptors |
| EP4104187A1 (de) | 2020-02-14 | 2022-12-21 | Novartis AG | Verfahren zur vorhersage des ansprechens auf eine chimäre antigen-rezeptor-therapie |
| EP4110376A2 (de) | 2020-02-27 | 2023-01-04 | Novartis AG | Verfahren zur herstellung von zellen mit expression des chimären antigenrezeptors |
| WO2022104061A1 (en) | 2020-11-13 | 2022-05-19 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
| TW202237850A (zh) | 2020-12-01 | 2022-10-01 | 賓州大學委員會 | 具有組織特異性靶向基序的新穎構成物及含有其之組成物 |
| AU2022262771A1 (en) | 2021-04-23 | 2023-11-02 | The Trustees Of The University Of Pennsylvania | Novel compositions with brain-specific targeting motifs and compositions containing same |
| TW202325845A (zh) | 2021-10-02 | 2023-07-01 | 賓州大學委員會 | 新穎aav衣殼及含其之組成物 |
| WO2023147304A1 (en) | 2022-01-25 | 2023-08-03 | The Trustees Of The University Of Pennsylvania | Aav capsids for improved heart transduction and detargeting of liver |
| WO2024056809A1 (en) | 2022-09-15 | 2024-03-21 | Novartis Ag | Treatment of autoimmune disorders using chimeric antigen receptor therapy |
| WO2024130070A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof |
| WO2024130067A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120727A (en) * | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
| US5162333A (en) * | 1991-09-11 | 1992-11-10 | American Home Products Corporation | Aminodiesters of rapamycin |
| ATE453709T1 (de) * | 1993-02-12 | 2010-01-15 | Univ Leland Stanford Junior | Regulierte transkription von zielgerichteten genen und andere biologische ereignisse |
| US5798355A (en) * | 1995-06-07 | 1998-08-25 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity |
| WO1996006097A1 (en) * | 1994-08-18 | 1996-02-29 | Ariad Gene Therapeutics, Inc. | New multimerizing agents |
| JP4936345B2 (ja) * | 1996-02-28 | 2012-05-23 | アリアド・ファーマシューティカルズ・インコーポレイテッド | イムノフィリン由来ドメインとのキメラタンパク質用の多量体化剤としてのラパマイシンの合成誘導体 |
-
1997
- 1997-02-28 JP JP53113997A patent/JP4936345B2/ja not_active Expired - Lifetime
- 1997-02-28 AT AT97907937T patent/ATE465149T1/de not_active IP Right Cessation
- 1997-02-28 CA CA002244363A patent/CA2244363C/en not_active Expired - Lifetime
- 1997-02-28 AU AU19809/97A patent/AU731826B2/en not_active Expired
- 1997-02-28 WO PCT/US1997/003137 patent/WO1997031898A1/en active Application Filing
- 1997-02-28 EP EP97907937A patent/EP0888303B1/de not_active Expired - Lifetime
- 1997-02-28 WO PCT/US1997/003157 patent/WO1997031899A1/en active Application Filing
- 1997-02-28 DE DE69739853T patent/DE69739853D1/de not_active Expired - Lifetime
- 1997-02-28 AU AU21927/97A patent/AU2192797A/en not_active Abandoned
-
2012
- 2012-01-10 JP JP2012002326A patent/JP2012131794A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP4936345B2 (ja) | 2012-05-23 |
| AU1980997A (en) | 1997-09-16 |
| CA2244363C (en) | 2006-11-14 |
| EP0888303A1 (de) | 1999-01-07 |
| DE69739853D1 (de) | 2010-06-02 |
| CA2244363A1 (en) | 1997-09-04 |
| AU731826B2 (en) | 2001-04-05 |
| JP2012131794A (ja) | 2012-07-12 |
| JP2000505475A (ja) | 2000-05-09 |
| WO1997031898A1 (en) | 1997-09-04 |
| EP0888303B1 (de) | 2010-04-21 |
| AU2192797A (en) | 1997-09-16 |
| WO1997031899A1 (en) | 1997-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE465149T1 (de) | Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen | |
| EP0776327A4 (de) | Neues multimerisierendes reagenz | |
| MY118498A (en) | Lactam derivatives | |
| DE69713402T2 (de) | Liganden des neuropeptids y | |
| EA200000048A1 (ru) | ИНГИБИТОРЫ ФАКТОРА Ха, СОДЕРЖАЩИЕ ГРУППУ С НЕЙТРАЛЬНОЙ P1-СПЕЦИФИЧНОСТЬЮ | |
| PT778277E (pt) | Derivados heterociclicos substituidos como antagonistas do crf | |
| BR9510420A (pt) | Azetidin-2-onas substituìdas para o tratamento de aterosclerose | |
| DE69331774T2 (de) | 7-Substituierte-8-substituierte-9-substituierte Amino-7-Demethyl-6-Deoxy-Tetracycline als antibiotische Mittel | |
| ES2187660T3 (es) | Derivados de rapamicina. | |
| DE69014141D1 (de) | Verwendung von Benzimidazol-Derivaten als antibakterielle Mittel. | |
| PL341239A1 (en) | Dihydrobenzofuranes | |
| ATE326512T1 (de) | Mischungen von beta-hydroxyalkylamiden und ihre verwendung als vernetzungsmittel bei der herstellung von pulverlacken | |
| DE69319349D1 (de) | Verwendung von aminen in ölzusammensetzungen | |
| ZA9410287B (en) | N-oxides of 4-arylpiperazines and 4-arylpiperidines | |
| DE69017627D1 (de) | Isochinolinderivate und ihre Salze als Proteasehemmer. | |
| DE69526097D1 (de) | Bicyclische carboxamide als 5-ht1a rezeptoren liganden | |
| AU3577295A (en) | Reagent for the determination of free radicals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |